DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Rosiglitazone (HB2556)
Description:Potent and selective PPARγ agonist. Promotes adipocyte differentiation and enhances NPC proliferation.
Purity:>99%
-
Rosiglitazone maleate (HB4140)
Description:Potent and selective PPARγ agonist; antidiabetic agent.
Purity:>98%
-
Rotenone (HB5398)
Description:Mitochondrial Complex I Inhibitor. Induces mitochondrial dysfunction.
Purity:>95%
-
RS-1 (HB5647)
Description:hRAD51 stimulator. Enhances CRISPR genome editing efficiency.
Purity:>99%
